[go: up one dir, main page]

BRPI0607172A2 - método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos - Google Patents

método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos

Info

Publication number
BRPI0607172A2
BRPI0607172A2 BRPI0607172-4A BRPI0607172A BRPI0607172A2 BR PI0607172 A2 BRPI0607172 A2 BR PI0607172A2 BR PI0607172 A BRPI0607172 A BR PI0607172A BR PI0607172 A2 BRPI0607172 A2 BR PI0607172A2
Authority
BR
Brazil
Prior art keywords
active substance
pharmaceutically active
medicaments
agent
patient
Prior art date
Application number
BRPI0607172-4A
Other languages
English (en)
Inventor
Thomas Hille
Werner Wessling
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of BRPI0607172A2 publication Critical patent/BRPI0607172A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

MéTODO PARA A MINISTRAçãO DE PELO MENOS UMA SUBSTáNCIA FARMACEUTICAMENTE ATIVA A UM PACIENTE, COMBINAçãO DE MEDICAMENTOS E USO DE PELO MENOS UMA SUBSTáNCIA FARMACEUTICAMENTE ATIVA PARA A FABRICAçãO DE UMA COMBINAçãO DE MEDICAMENTOS. A presente invenção refere-se a um método para a ministração de pelo menos um agente farmacêutico a um paciente o qual é dependente da ministração do referido agente, ou agentes, que compreende: (a) a aplicação de pelo menos um sistema terapêutico transdérmico que contém um primeiro agente farmacêutico para a ministração transdérmica do referido agente durante um período pré-determinado e (b) a aplicação de pelo menos uma pastilha em camadas no começo ou durante o período da ministração transdérmica, no qual a pastilha em camadas contém o mesmo agente ou um segundo agente ou ainda mais agentes adequados para a mesma indicação como a do primeiro agente.
BRPI0607172-4A 2005-02-21 2006-02-14 método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos BRPI0607172A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005007859A DE102005007859A1 (de) 2005-02-21 2005-02-21 Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
PCT/EP2006/001312 WO2006087160A1 (de) 2005-02-21 2006-02-14 Verfahren für eine medikamentöse kombinations- behandlung, sowie hierfür geeignete arzneimittel -kombinationen

Publications (1)

Publication Number Publication Date
BRPI0607172A2 true BRPI0607172A2 (pt) 2009-08-11

Family

ID=36591258

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607172-4A BRPI0607172A2 (pt) 2005-02-21 2006-02-14 método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos

Country Status (16)

Country Link
US (1) US20080160068A1 (pt)
EP (1) EP1850836B1 (pt)
JP (1) JP5134973B2 (pt)
KR (1) KR101267771B1 (pt)
CN (1) CN101155578B (pt)
AU (1) AU2006215805B2 (pt)
BR (1) BRPI0607172A2 (pt)
CA (1) CA2598406C (pt)
DE (1) DE102005007859A1 (pt)
ES (1) ES2459203T3 (pt)
IL (1) IL185377A0 (pt)
MX (1) MX2007009968A (pt)
NZ (1) NZ590981A (pt)
RU (1) RU2376984C2 (pt)
WO (1) WO2006087160A1 (pt)
ZA (1) ZA200706640B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
DE102006027793A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Opioid-Kombinations-Wafer
SI2054031T1 (sl) 2006-07-21 2016-09-30 Biodelivery Sciences International, Inc. Transmukozne naprave za administracijo z izboljšanim vnosom
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
SG10202012743WA (en) * 2011-12-21 2021-01-28 Biodelivery Sciences Int Inc Transmucosal drug delivery devices for use in chronic pain relief
US8946253B2 (en) 2012-04-17 2015-02-03 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3645000A4 (en) 2017-06-30 2021-03-24 Purdue Pharma L.P. METHOD OF TREATMENT AND DOSAGE FORMS THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
SK284994B6 (sk) * 1997-05-30 2006-04-06 Neurosearch A/S Deriváty 8-azabicyklo[3.2.1]okt-2-énu, spôsob ich prípravy a ich použitie
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
AU2003224742A1 (en) * 2002-03-20 2003-10-08 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
DE10230558B4 (de) * 2002-07-05 2007-08-02 Lts Lohmann Therapie-Systeme Ag Medizinisches Set zur Verabreichung in einer Kombinationstherapie
DE10256775A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Filmförmige Zubereitungen zur transmucosalen Verabreichung von Nicotin, sowie Verfahren zu deren Herstellung
DE10301930A1 (de) * 2003-01-17 2004-07-29 Frank Becher Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung

Also Published As

Publication number Publication date
RU2007133435A (ru) 2009-03-20
IL185377A0 (en) 2008-02-09
ES2459203T3 (es) 2014-05-08
JP2008530158A (ja) 2008-08-07
ZA200706640B (en) 2008-06-25
NZ590981A (en) 2012-09-28
MX2007009968A (es) 2007-10-10
DE102005007859A1 (de) 2006-08-24
US20080160068A1 (en) 2008-07-03
CA2598406C (en) 2014-03-25
CA2598406A1 (en) 2006-08-24
EP1850836B1 (de) 2014-04-02
KR20070108245A (ko) 2007-11-08
AU2006215805A1 (en) 2006-08-24
WO2006087160A1 (de) 2006-08-24
KR101267771B1 (ko) 2013-05-24
AU2006215805B2 (en) 2012-03-15
JP5134973B2 (ja) 2013-01-30
RU2376984C2 (ru) 2009-12-27
CN101155578B (zh) 2010-12-01
EP1850836A1 (de) 2007-11-07
CN101155578A (zh) 2008-04-02

Similar Documents

Publication Publication Date Title
Schug et al. Fentanyl formulations in the management of pain: an update
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
Minkowitz et al. Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
US20130072532A1 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
BRPI0518622A2 (pt) usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
AR070842A1 (es) Regimen de dosificacion para un agonista de receptor selectivo de s1p1
BRPI0519471A2 (pt) formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo
IN2014DN09817A (pt)
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
PE20081464A1 (es) Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
NZ591408A (en) Paracetamol and Calcium carbonate composition
EP3829572A1 (en) Use of neurokinin-1 antagonists to treat chronic pruritus
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
Sturn et al. Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
BR112012014107B8 (pt) sistema terapêutico transdérmico (tts) e processo de produção de tts
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
BRPI0520797A2 (pt) forma de dosagem farmacêutica, comprimido farmacêutico, método para quebrar um comprimido farmacêutico, método de administração de uma dose parcial de uma droga contida em um comprimido farmacêutico, método para reduzir o risco ou impedir a confusão do paciente em um tratamento, comprimido farmacêutico prensado, método para quebrar um comprimido farmacêutico prensado e método para a criação de uma quantidade precisa de uma droga
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2468 DE 24/04/2018 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL